Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

FuelCell Energy FCEL is trading below its 50-day and 200-day simple moving average (SMA), signaling a bearish trend. FCEL ...

SonicWall, which learned about the zero-day from Microsoft, initially said it was aware of “possible active exploitation”, ...

CLX looks poised for growth through recent recovery, improved distribution channels and focus on innovation and expansion ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...

The company also plans to initiate the Phase 2 OPAL trial in mid-2025 to study apitegromab in SMA patients under two years of age. Apitegromab is a fully human monoclonal antibody that inhibits ...

DLTR's store and product expansion is promising, yet rising expenses and soft discretionary demand weigh on performance.

Scholar Rock is asking the U.S. Food and Drug Administration to approve apitegromab for people with spinal muscular atrophy.

In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...

The company has emphasized its commitment to advancing care for individuals with SMA through this latest development. The review of the higher dose regimen by the FDA and EMA marks a significant ...